1. Home
  2. LIDR vs IMA Comparison

LIDR vs IMA Comparison

Compare LIDR & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

HOLD

Current Price

$1.13

Market Cap

61.6M

ML Signal

HOLD

IMA

ImageneBio Inc.

N/A

Current Price

$5.79

Market Cap

66.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LIDR
IMA
Founded
2013
2019
Country
United States
United States
Employees
56
17
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6M
66.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIDR
IMA
Price
$1.13
$5.79
Analyst Decision
Strong Buy
Hold
Analyst Count
2
2
Target Price
$4.75
$16.00
AVG Volume (30 Days)
664.2K
8.4K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2,604.29
N/A
Revenue Next Year
$466.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$3.94
52 Week High
$6.44
$17.50

Technical Indicators

Market Signals
Indicator
LIDR
IMA
Relative Strength Index (RSI) 28.36 43.53
Support Level N/A $5.36
Resistance Level $1.77 $6.13
Average True Range (ATR) 0.07 0.31
MACD 0.00 -0.04
Stochastic Oscillator 3.19 22.45

Price Performance

Historical Comparison
LIDR
IMA

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: